Rakuten Securities Inc. Purchases 550 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Rakuten Securities Inc. boosted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 68.3% during the 4th quarter, HoldingsChannel reports. The fund owned 1,355 shares of the company’s stock after buying an additional 550 shares during the quarter. Rakuten Securities Inc.’s holdings in TransMedics Group were worth $84,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quarry LP increased its stake in TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares during the period. National Bank of Canada FI increased its stake in TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares during the period. Farther Finance Advisors LLC increased its stake in TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after acquiring an additional 316 shares during the period. Hager Investment Management Services LLC bought a new position in TransMedics Group during the fourth quarter valued at about $33,000. Finally, Sachetta LLC bought a new position in TransMedics Group during the fourth quarter valued at about $40,000. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TMDX shares. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Piper Sandler lowered their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. TD Cowen lowered their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, TransMedics Group presently has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Stock Down 0.8 %

Shares of TMDX opened at $67.08 on Thursday. The company has a market capitalization of $2.26 billion, a P/E ratio of 71.36 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The business’s 50 day simple moving average is $68.64 and its 200-day simple moving average is $95.47.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.